Free Trial

Myriad Genetics (MYGN) Stock Price, News & Analysis

Myriad Genetics logo
$5.06 +0.06 (+1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$5.06 0.00 (-0.10%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Myriad Genetics Stock (NASDAQ:MYGN)

Key Stats

Today's Range
$4.99
$5.20
50-Day Range
$3.84
$5.72
52-Week Range
$3.81
$29.30
Volume
2.93 million shs
Average Volume
1.28 million shs
Market Capitalization
$466.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.38
Consensus Rating
Hold

Company Overview

Myriad Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

MYGN MarketRank™: 

Myriad Genetics scored higher than 92% of companies evaluated by MarketBeat, and ranked 95th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 10 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Myriad Genetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Myriad Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Myriad Genetics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Myriad Genetics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Myriad Genetics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Myriad Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    8.31% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently decreased by 10.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Myriad Genetics does not currently pay a dividend.

  • Dividend Growth

    Myriad Genetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.31% of the float of Myriad Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Myriad Genetics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Myriad Genetics has recently decreased by 10.74%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Myriad Genetics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Myriad Genetics this week, compared to 8 articles on an average week.
  • Search Interest

    Only 1 people have searched for MYGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.10% of the stock of Myriad Genetics is held by insiders.

  • Percentage Held by Institutions

    99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Myriad Genetics' insider trading history.
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

Myriad Genetics Earns 2025 Great Place To Work Certification™
MYGN Myriad Genetics, Inc. - Seeking Alpha
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. With gold at record highs and Bridgewater now buying in, one analyst believes Buffett’s next move could hit by August 15th. He’s identified the gold miner that fits Buffett’s profile — plus four smaller plays with even more upside.
See More Headlines

MYGN Stock Analysis - Frequently Asked Questions

Myriad Genetics' stock was trading at $13.71 at the beginning of 2025. Since then, MYGN stock has decreased by 63.1% and is now trading at $5.06.

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Tuesday, May, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The company's revenue for the quarter was down 33.6% on a year-over-year basis.
Read the conference call transcript
.

Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and others.

Myriad Genetics' top institutional shareholders include Assenagon Asset Management S.A. (0.35%), Public Employees Retirement System of Ohio (0.06%), State of Alaska Department of Revenue (0.06%) and Wealth Enhancement Advisory Services LLC (0.03%). Insiders that own company stock include Paul J Diaz, Richard Bryan Riggsbee, Nicole Lambert, Heinrich Dreismann, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman.
View institutional ownership trends
.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

Last Earnings
5/06/2025
Today
7/16/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MYGN
CIK
899923
Employees
2,700
Year Founded
1991

Price Target and Rating

High Price Target
$30.00
Low Price Target
$6.00
Potential Upside/Downside
+185.0%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.30 million
Net Margins
-12.20%
Pretax Margin
-15.28%
Return on Equity
-4.95%
Return on Assets
-3.39%

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
1.90
Quick Ratio
1.71

Sales & Book Value

Annual Sales
$837.60 million
Price / Sales
0.56
Cash Flow
$0.97 per share
Price / Cash Flow
5.22
Book Value
$7.70 per share
Price / Book
0.66

Miscellaneous

Outstanding Shares
92,180,000
Free Float
90,241,000
Market Cap
$465.23 million
Optionable
Optionable
Beta
1.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MYGN) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners